Browse studies

Find your next paid study

26,753 recruiting studies available now

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and p…

Non-small Cell Lung Cancer

Estimated

~$10 – $7,500

AstraZenecaNCT05061550

Phase 1

Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study

This 24-month study is testing whether adding AdiaVita, an umbilical cord blood-derived stem cell and exosome product, to glutathione therapy helps improve aut…

Autism Spectrum DisorderAutismASD+1 more

Documented

$12,000

Adia Med of Winter Park LLCNCT07304440

Phase 1

TulmiSTAR-01: A Two-part, Phase I Dose Escalation and Expansion Followed by a Randomized, Open-label Multicenter, Phase II Study to Assess the Safety and Efficacy of the Combination of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) vs Standard of Care in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462…

Progressive Metastatic Castrate Resistant Prostate Cancer

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07206056

Phase 2

A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants With Advanced Prostate Cancer

Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone…

Prostate CancerMetastatic Castration-Resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer

Estimated

~$10 – $8,750

Astellas Pharma Global Development, Inc.NCT07005154

Phase 4

Itraconazole Therapy In Bronchiectasis With Airway Mold: A Single-Arm Pilot Trial Of Feasibility, Safety, And Impact On Respiratory Symptoms And Airway Microbiome Diversity

The primary objective of this study is to evaluate the feasibility of itraconazole therapy in patients with bronchiectasis and airway mold. Feasibility will be…

BronchiectasisFungal Infection of Upper Respiratory Tract

Estimated

~$10 – $6,250

Mayo ClinicNCT07283497

Phase 2

A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes

The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or o…

ObesityOverweightDiabetes Mellitus, Type 2

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07215559

Phase 2

ISA2 to Master Protocol ARGX-999-2-MG-2000 - an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are an…

AChR-Ab Seropositive Generalized Myasthenia GravisMyasthenia Gravis (MG)MG - Myasthenia Gravis+1 more

Control Network Neuromodulation to Enhance Cognitive Training in Complex Traumatic Brain Injury

The CONNECT-TBI Trial aims to develop safe, effective treatments for complex mTBI that improve cognitive functioning. Based on the compelling preliminary data …

Traumatic Brain Injury

Estimated

~$10 – $6,250

University of New MexicoNCT05236010

Phase 1

An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Participants With Small Cell Lung Cancer

An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, effic…

SCLC

Estimated

~$10 – $8,750

Zai Lab (Shanghai) Co., Ltd.NCT06179069

Phase 3

A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients With BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (EvoPAR-Prostate02).

The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen depriva…

Prostate Cancer

Estimated

~$10 – $7,500

AstraZenecaNCT06952803

Observational

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

This study proposes to develop an MRI technique named Coronary Atherosclerosis T1-weighed Characterization (CATCH) that will improve the quality and reliabilit…

Coronary Atherosclerosis

Estimated

~$10 – $6,250

Cedars-Sinai Medical CenterNCT03504956

A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to…

Myasthenia GravisMGgMG+3 more

Estimated

~$10 – $7,500

argenxNCT07294170